NCT00210288已完成2 期
A Comparative Double Blind Placebo-Controlled Study of Immunogenicity and Safety of Two Doses 10^5 and 10^7 CFU of SC599 Oral Vaccine, a Live Attenuated Shigella Dysenteriae 1 Vaccine Strain in Healthy Human Adult Volunteers
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 111
- 试验地点
- 4
- 主要终点
- Immune response assessed by the proportion of Immunoglobulin A (IgA) anti-Lipopolysaccharide (LPS) Antibody-Secreting Cells (ASC) responders.
研究概览
简要总结
The purpose of this study is to assess the immune response produced by two doses of SC599 vaccine compared to placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Adult volunteers age 18 to 50
- •Signed Informed Consent form following a detailed written explanation of participation in the protocol
- •Volunteers who are in good health as determined by medical history, physical examination and clinical judgement
- •Volunteers who will be available and "normally reside within the M25" (England) or in Paris and Paris suburb (France) and not leave England or France for the duration of the study
- •Women who agree to have a pregnancy test immediately before immunisation and to use effective contraception during the study period
- •Volunteers eligible for free NHI treatment (England), volunteers who are covered by social security (France)
排除标准
- •Individuals who have hypersensitivity to any component of the vaccines used in this study.
- •Individuals who have hypersensitivity to ciprofloxacin
- •Individuals who are found to be HIV or HCV antibody positive or Hepatitis B surface antigen positive at the time of initial screening
- •Individuals who are found to have HLA-B27 tissue type at the time of initial screening
- •Individuals with a known or suspected history of gastrointestinal disease or abnormality
- •Concomitant therapy with antibiotics, iron, zinc, H2-receptor antagonists or proton pump inhibitors
- •Individuals who have received any vaccine against Shigella or had proven or suspected shigellosis (bloody diarrhoea with fever) within 6 months prior to study entry
- •Individuals with a significant level of immunity against Shigella detected at the screening visit (defined as serum ELISA anti-LPS IgG antibody titre greater than 3 S.D. above the mean background activity of a bank of healthy human sera)
- •A Clinically significant amount of protein or haemoglobin in the urine sample at the screening visit
- •A Clinically significant abnormality in the haematological or biochemical assays (an abnormal value will be defined by the ranges quoted in each centre) at the screening visit
- •A positive Shigella stool culture at the screening visit
- •Individuals with a known impairment of immune function or those receiving immunosuppressive therapy (including systemic corticosteroids). Inhaled or topical steroid preparation are not a non-inclusion criterion
- •Individuals with acute infections (including fever > 37.5°C oral temperature)at the time of immunisation or any chronic disease
- •Women capable of becoming pregnant who do not agree to have pregnancy testing before immunisation, or who do not agree to take effective contraception during the study period
- •Breastfeeding women
- •Individuals with a current problem with substance abuse or with a history of substance abuse which in the opinion of the investigator, might interfere with participation in the study
- •Individuals with any condition which, in the opinion of the investigator, might interfere with the evaluation with the study objectives
- •Individuals who have received an investigational product within 30 days prior to entry
- •Individuals who cannot read, speak fluent French or English according to the investigational site setting
- •Individuals who are planning to leave England or France prior to the end of the study period or who are likely not to complete the study
- •Individuals who have persons living with them who in the opinion of the investigator may be at risk of disease if exposed to the vaccine strain or whose occupation may bring them into contact with persons at risk of disease or who are food handlers by occupation
- •Individuals with close household contact with child younger than 5 years or a person with immunodeficiency
结局指标
主要结局
Immune response assessed by the proportion of Immunoglobulin A (IgA) anti-Lipopolysaccharide (LPS) Antibody-Secreting Cells (ASC) responders.
次要结局
- -The safety will be evaluated by the proportions of clinical and biological adverse events. Illness after vaccination will be defined as either diarrhoea or fever.
- -Proportion of volunteers who have a B subunit antibody response
- -Proportion of volunteers who have a LPS response
- 2) SC599 Shedding
- -Proportion of volunteers who will excrete the vaccine strain and by the duration of the SC5999 shedding, defined as the time (days) between the first an last stool that were positive for SC599.
- 3) Safety Assessment
- 1) Immune Response:
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
A Study to Evaluate the Safety and Ability of the Vaccine to Induce Antibodies Against the Respiratory Syncytial Virus in Healthy AdultsRespiratory Syncytial Virus (RSV)NCT02298179GlaxoSmithKline288
已完成
1 期
Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected AdultsHealthyNCT02788045Janssen Vaccines & Prevention B.V.201
已完成
2 期
Phase 2a Immunogenicity Study of Hantaan/Puumala Virus DNA Vaccine for Prevention of Hemorrhagic FeverHemorrhagic Fever With Renal SyndromeNCT02116205U.S. Army Medical Research and Development Command130
已完成
1 期
Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy ParticipantsVirus, ZikaFlavivirus InfectionsHealthy ParticipantsZika Virus DiseaseNCT03343626Takeda271
已完成
2 期
A Study to Evaluate a Range of Dose Levels of an Adenovirus Serotype 26 (Ad26.RSV.preF)-Based Vaccine in Older AdultsHealthyNCT04453202Janssen Vaccines & Prevention B.V.459